Affiris, a biotech company based in Austria, and the Michael J Fox Foundation, have announced the latest results of a vaccine they have been developing to treat Parkinson’s disease. Following the first…
Academic rigour, journalistic flair
Articles on Vaccine development
Displaying 61 - 70 of 70 articles
All scientists have that moment when an idea is initiated or when things come together and a project flourishes. One such moment for me came at a Keystone scientific meeting in South Carolina in 1994…
Researchers from Vanderbilt University have discovered a new method of vaccination where tiny gold particles target immune…
The 2009 influenza pandemic prompted the fastest effort in history to develop a vaccine. Within six months of the pandemic declaration, vaccine-makers had developed, produced and distributed hundreds of…
The first ever “atlas” of T cells in the human body has been created, providing a unique view of how the cells function in…
Today we are launching Equivac® HeV, the world’s first commercially available Hendra vaccine for horses. This breakthrough is the culmination of a scientific journey that dates back to the emergence of…
Despite three decades of research, an HIV vaccine remains elusive. The main reason for this is the virus’s uncanny ability to evolve resistance to immune control, so understanding how the virus adapts…
The great burden of death and disease caused by the malaria parasite often goes unnoticed in the developed world. But it’s the leading cause of death in children under five years old in many sub-Sahara…
Injecting mice with simple baker’s yeast protects against the fatal fungal infection, aspergillosis, according to research…
Hepatitis C is a blood-borne virus that infects about 3% of the world’s population. It’s a significant cause of both illness and death due to cirrhosis (advanced liver scarring) and liver cancer. By the…
Top contributors
-
Associate Professor of Viral Immunology, Department of Pathobiology, University of Guelph
-
Professor of Immunology and Associate Dean, Research and Graduate Studies, University of Guelph
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate Professor, School of Population Health, UNSW Sydney
-
Infectious Diseases Specialist and Clinical Professor, University of Tasmania
-
Senior Project Manager, Jenner Institute, University of Oxford
-
Vaccine Knowledge Project Manager, University of Oxford
-
Professor of Immunology, RMIT University
-
Associate Professor of Bioethics, University of Portsmouth
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Ph.D. Candidate in Chemical & Physical Biology, Vanderbilt Vaccine Center, Vanderbilt University
-
Clinician-scientist, Laboratory Medicine and Pathobiology, University of Toronto
-
Ph.D. Student in Microbiology and Immunology, Vanderbilt Vaccine Center, Vanderbilt University
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Professor, Infectious Diseases and Microbiology, The University of Queensland
